Company profile
Vanda Pharmaceuticals Inc.
NASDAQ: VNDA · Healthcare · Biotechnology
#286 of 1,418 Healthcare companies by revenue54th-percentile growth
EA Score
63CFH 49DQ 85GM 56SS 76
v0.1 · 65/100 weight · provisional
↑ disclosure history, workforce scale · ↓ Piotroski F, 3-yr revenue growth
Methodology →Revenue TTM
$217.8M
Rev growth YoY (TTM)
+8.2%
Net income (FY)
-$220.5M
Employees
533
as of 2026-08-12
Market cap
$296.5M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$216.1M$216.1M2025
Net income-$220.5M-$220.5M2025
Operating income-$151.2M-$151.2M2025
Total assets$488.9M$488.9M2025
Liabilities$161.8M$161.8M2025
Equity$327.2M$327.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Fanapt62%
Hetlioz38%
By geography
Not disclosed.
The read
What is Vanda Pharmaceuticals Inc.’s revenue?
Vanda Pharmaceuticals Inc. booked $216.1M in FY2025 revenue, growing 8.7% year over year — about the middle of the pack among Healthcare companies we track, at a -102.0% net margin.
Peers · Healthcare
Puma Biotechnology, Inc.72BAxoGen, Inc.80B+IDEAYA Biosciences, Inc.67BTreace Medical Concepts, Inc.55CEstablishment Labs Holdings Inc.59CCanopy Growth Corporation59CNeighbors
District of Columbia →Key facts
CEOMihael H. Polymeropoulos
SectorHealthcare
IndustryBiotechnology
HeadquartersWashington, DC
ExchangeNASDAQ: VNDA
Employees533
IPO date2006-04-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.